Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This single-center, open-label study will evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Baylor Research Institute
• Treatments: Heparin

Criteria

Inclusion Criteria:

1. Male or female ≥ 18 years of age

2. Respiratory failure requiring VV-ECMO support

3. Subject or appointed health care proxy/LAR is able to understand and sign the informed consent form

Exclusion Criteria:

1. Subject currently enrolled in another interventional research trial

2. History of hypersensitivity/adverse reaction to heparin

3. Proven Heparin induced thrombocytopenia (HIT)

4. History of patent foramen ovale (PFO)

5. Recent surgery or other contraindication to systemic anticoagulation, e.g. intracranial bleed

6. Medical indication other than ECMO for systemic anticoagulation, e.g. pulmonary embolism